Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Carcinoma, Non-Small-Cell Lung 10Triple Negative Breast Neoplasms 8Squamous Cell Carcinoma of Head and Neck 5Breast Neoplasms 5Head and Neck Neoplasms 4Turcot syndrome 3Melanoma 3Lung Neoplasms 3Colorectal Neoplasms 3Cholangiocarcinoma 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Hodgkin Disease 2Glioblastoma 2Endometrial Neoplasms 2Colonic Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Brain Neoplasms 2Biliary Tract Neoplasms 2Advanced Endometrial Cancer 2Urinary Bladder Neoplasms 1Tongue Neoplasms 1To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1Thyroid Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Squamous NSCLC 1

Interventions

pembrolizumab 2lenvatinib 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Advanced Endometrial Cancer × pembrolizumab × Clear all
NCT05077215 2025-12-08

Efficacy and Safety of a Repurposed Drug Added to the Combination of Len Plus Pem in Advanced Endometrial Cancer

Evergreen Therapeutics, Inc.

Phase 3 Not yet recruiting
450 enrolled
Gynecologic

Advanced Endometrial Cancer

NCT05106127 2025-12-08

Safety Lead-In Study of a Repurposed Drug Added to the Combination of Len Plus Pem

Evergreen Therapeutics, Inc.

Phase 2 Not yet recruiting
28 enrolled
Gynecologic

Advanced Endometrial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡